Premium
A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega‐3 fatty acids from different sources in facilitating cardiovascular disease risk reduction (LB329)
Author(s) -
Laidlaw Maggie,
Cockerline Carla,
Rowe William
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.lb329
Subject(s) - fish oil , medicine , randomized controlled trial , docosahexaenoic acid , triglyceride , eicosapentaenoic acid , fatty acid , bioavailability , omega 3 fatty acid , polyunsaturated fatty acid , food science , chemistry , biochemistry , pharmacology , fish <actinopterygii> , cholesterol , biology , fishery
A randomized clinical trial to determine the efficacy of manufacturers’ recommended doses of omega‐3 fatty acids from different sources in facilitating cardiovascular disease risk reduction Maggie Laidlaw 1 , Carla A. Cockerline 1 , William J. Rowe: 1 1 Nutrasource Diagnostics Inc. Omega‐3 fatty acids confer beneficial health effects, but North Americans are lacking in their dietary omega‐3‐rich intake. Omega‐3 supplementation is an alternative to dietary consumption of fish; however, not all omega‐3 products are created equal. The trial objective was to assess changes in cardiovascular risk following supplementation with four omega‐3 supplements. This was an open‐label, randomized, cross‐over study with thirty‐five healthy subjects. Supplement daily doses (as recommended on product labels) were: Concentrated Triglyceride (rTG) fish oil: EPA 650 mg, DHA 450 mg Ethyl Ester (EE) fish oil: EPA 756 mg, DHA 228 mg Phospholipid (PL) krill oil: EPA 150 mg, DHA 90 mg Triglyceride (TG) salmon oil: EPA 180 mg, DHA 220 mg For the duration of the study, participants were randomly assigned to consume one of the four products, in random order, for a 28‐day period, followed by a 4‐week washout period. This process continued until each subject had consumed each product. Blood samples before and after supplementation were quantified for fatty acid analysis by gas chromatography flame ionization, and statistically analysed using ANOVA for repeated measures. At the prescribed dosage, rTG was statistically superior to all three comparators in the bioavailability of EPA+DHA. Risk reduction in several elements of cardiovascular disease was achieved to a greater extent by rTG than by any other supplement. PL and TG were relatively unsuccessful in this aspect of the study. For the general population, the type and dose of omega‐3 supplements may be immaterial. However, the type and dose of omega‐3 supplementation may be important for those interested in reducing their risk of cardiovascular disease.